Iovance Biotherapeutics (IOVA) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free IOVA Stock Alerts $10.24 -0.19 (-1.82%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 1:38 AM | americanbankingnews.comVaxart (NASDAQ:VXRT) vs. Iovance Biotherapeutics (NASDAQ:IOVA) Financial ComparisonMay 17 at 5:15 PM | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16 at 9:30 AM | fool.com4 Small-Cap Value Stocks That Could Go ParabolicMay 13, 2024 | benzinga.comLooking At Iovance Biotherapeutics's Recent Unusual Options ActivityMay 13, 2024 | seekingalpha.comIovance Biotherapeutics' Amtagvi: Innovative Therapy, Financial Strain (Rating Downgrade)May 13, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from HC WainwrightMay 12, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down to $13.45May 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11, 2024 | markets.businessinsider.comIovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical AdvancementsMay 11, 2024 | fool.comIovance Biotherapeutics Reports a Q1 Revenue MissMay 11, 2024 | finance.yahoo.comIovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...May 11, 2024 | msn.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPSIovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.99 million. During the same quarter in the prior year, the business earned ($0.50) earnings per share. The firm's quarterly revenue was up 71400.0% compared to the same quarter last year.May 10, 2024 | benzinga.comIovance Biotherapeutics's Options: A Look at What the Big Money is ThinkingMay 10, 2024 | seekingalpha.comIovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On AmtagviMay 10, 2024 | fool.comWhy Iovance Stock Is Down 18% TodayMay 10, 2024 | markets.businessinsider.comIovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch SuccessMay 9, 2024 | investorplace.comIOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | sfgate.comIovance Biotherapeutics: Q1 Earnings SnapshotMay 9, 2024 | finance.yahoo.comIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 9, 2024 | globenewswire.comIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 6, 2024 | marketbeat.comInvestors Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the target of some unusual options trading activity on Monday. Investors bought 23,866 call options on the company. This is an increase of 44% compared to the typical volume of 16,524 call options.May 5, 2024 | fool.comGot $500? These Hot Growth Stocks Are Screaming Buys Right NowMay 2, 2024 | marketbeat.comIovance Biotherapeutics (IOVA) to Release Quarterly Earnings on ThursdayIovance Biotherapeutics (NASDAQ:IOVA) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | msn.comFirst FDA-approved cellular therapy for metastatic melanoma available in South FloridaMay 1, 2024 | globenewswire.comIovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024May 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)April 30, 2024 | globenewswire.comIovance Biotherapeutics to Present at Upcoming ConferencesApril 28, 2024 | fool.comWhere Will Iovance Biotherapeutics Stock Be in 5 Years?April 28, 2024 | marketbeat.comParametrica Management Ltd Acquires 224,876 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Parametrica Management Ltd lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 235.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 320,276 shares of the biotechnology company's stockApril 27, 2024 | investorplace.comThe Top 3 Biotech Stocks to Buy in April 2024April 27, 2024 | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been assigned an average recommendation of "Buy" from the ten ratings firms that are covering the company, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 mApril 24, 2024 | globenewswire.comIovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual MeetingApril 21, 2024 | fool.comThese Biotech Stocks Could Soar 120% and 295%, According to Wall StreetApril 19, 2024 | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)April 17, 2024 | marketbeat.comIovance Biotherapeutics, Inc. Expected to Earn FY2024 Earnings of ($1.57) Per Share (NASDAQ:IOVA)Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Analysts at Zacks Research dropped their FY2024 earnings estimates for Iovance Biotherapeutics in a report issued on Monday, April 15th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($1.57) per sApril 17, 2024 | fool.comIs Iovance Biotherapeutics Stock a Buy Now?April 17, 2024 | nasdaq.comIovance Biotherapeutics Enters Oversold Territory (IOVA)April 17, 2024 | nasdaq.comFirst Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)April 17, 2024 | finance.yahoo.comMarket Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 9, 2024 | marketbeat.comThe Top 5 Analysts Ranked by Marketbeat and Stocks They CoverMarketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.April 9, 2024 | marketbeat.comThe Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (IOVA)Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.April 9, 2024 | seekingalpha.comIovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent ResultsApril 8, 2024 | marketbeat.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Down 3.7% Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 3.7%April 5, 2024 | fool.comBetter Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR TherapeuticsApril 5, 2024 | marketbeat.comVanguard Group Inc. Purchases 1,748,082 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)Vanguard Group Inc. lifted its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 8.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,143,470 shares of the biotechnology compApril 3, 2024 | bizjournals.comObsidian lands $160M Series C —but IPO still in the cardsApril 3, 2024 | markets.businessinsider.comBuy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in ImmunotherapyApril 3, 2024 | marketbeat.comSG Americas Securities LLC Sells 187,664 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)SG Americas Securities LLC lessened its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 67.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 88,729 shares of the biotechnology companyApril 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA) Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. IOVA Media Mentions By Week IOVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOVA News Sentiment▼0.540.42▲Average Medical News Sentiment IOVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOVA Articles This Week▼66▲IOVA Articles Average Week Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Immunovant News Today SpringWorks Therapeutics News Today Krystal Biotech News Today CRISPR Therapeutics News Today Immunocore News Today Arcellx News Today Halozyme Therapeutics News Today Twist Bioscience News Today Denali Therapeutics News Today Vericel News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOVA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
